查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1603845

到 2030 年肺炎链球菌疫苗的市场预测：按产品类型、疫苗类型、年龄层、分销管道、最终用户和地区进行的全球分析

Pneumococcal Vaccine Market Forecasts to 2030 - Global Analysis By Product Type, Vaccine Type, Age Group, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC的数据，2024年全球肺炎链球菌疫苗市场规模为88亿美元，预计2030年将达到130.8亿美元，预测期内复合年增长率为6.8%。

肺炎链球菌疫苗接种是一种预防由肺炎链球菌引起的感染疾病的疫苗，这种感染会引起败血症、脑膜炎和肺炎等严重症状。两种主要类型是肺炎链球菌结合疫苗（PCV）如PCV13和肺炎链球菌多醣体疫苗（PPSV）如PPSV23。这些疫苗接种对于幼儿、老年人和免疫力较弱的人等弱势群体尤其重要。这些疫苗的作用是提高免疫系统识别和攻击肺炎球菌的能力。

根据联合国国际儿童紧急基金会（UNICEF）2023年11月发布的资料，全球整体每天约有2,000名儿童受到肺炎影响。

肺炎链球菌疾病的盛行率增加

对肺炎链球菌疫苗的需求主要是由肺炎球菌疾病（包括脑膜炎和肺炎）发生率的上升所推动的。这些感染疾病给全球健康带来了巨大的负担，特别是当它们影响幼儿和老年人时。有效免疫接种的可用性以及人们对肺炎链球菌感染相关严重健康风险的认识不断提高，正在推动市场扩张。随着全球医疗保健系统更加重视公共卫生宣传活动和预防措施，对肺炎链球菌疫苗接种的需求预计将逐渐增加。

供应链中断

肺炎链球菌疫苗产业受到生产和供应链中断的严重影响，这可能导致疫苗短缺、疫苗接种计划推迟并危及公共卫生工作。原材料短缺或严格的品管要求等製造问题会扰乱生产，从而导致此类中断。此外，疫苗的及时分发将受到后勤挑战的阻碍，包括低温运输基础设施不足、运输延误和地缘政治因素，特别是在农村和低收入地区。

提高认识和疫苗接种计划

意识和免疫计划推动了肺炎球菌疫苗市场的发展，因为世界卫生组织 (WHO) 和联合国儿童基金会等组织的政府倡议和宣传活动旨在教育公众了解肺炎球菌感染的危险，这是一个重要因素。为了鼓励及早接种疫苗并阻止疾病传播，这些倡议主要针对老年人和新生儿等高风险族群。广泛的免疫宣传活动正在增加免疫接种的机会，促进全球公共卫生成果，并促进整体市场成长，特别是在低收入和中等收入国家。

疫苗接种费用高

肺炎链球菌疫苗接种的高昂费用是低收入者和医疗保健预算有限的国家获得疫苗接种的主要障碍。 PPSV23 和 Prevnal 13 等疫苗需要先进的製造技术来生产，这使得它们变得昂贵。儘管一些公共卫生倡议免费或以大幅折扣提供疫苗，但财政限制仍可能阻碍普遍接种。这种成本障碍在低度开发国家尤其成问题，许多人由于自付费用而迴避疫苗接种，影响了整体疫苗接种覆盖率并增加了疾病风险。

COVID-19 的影响

肺炎链球菌疫苗市场受到COVID-19大流行的显着影响，机会与挑战并存。最初，免疫计划因医疗服务和供应链中断而受到阻碍，导致疫苗接种计划延迟。然而，由于大流行，肺炎球菌疫苗的需求量很大，这提高了人们对呼吸道疾病的认识并扩大了公共卫生宣传活动。预防肺炎的需要，特别是针对弱势族群的肺炎，促使各国政府加强了疫苗接种力道。因此，随着医疗保健系统的调整以及肺炎球菌疫苗接种与 COVID-19倡议同等重要，市场预计将扩大。

预计儿科领域在预测期内将是最大的。

据估计，儿科市场是最大的。新生儿和幼儿中肺炎球菌疾病（包括脑膜炎和肺炎）的高盛行率构成了重大的健康风险。由于强调儿童疫苗重要性的政府措施和公共卫生计划，需求不断增加。有效的肺炎球菌疫苗的可用性以及家长对免疫接种益处的了解的增加进一步推动了小儿科领域的市场扩张。

在预测期内，医院/诊所产业预计复合年增长率最高

预计医院和诊所产业在预测期内的复合年增长率最高。这些医疗保健中心对于为弱势群体，特别是幼儿、老年人和免疫力较弱的人提供疫苗接种至关重要。鼓励卫生保健专业人员透过政府促进免疫计画和疫苗接种报销政策提供肺炎球菌疫苗。此外，肺炎链球菌感染的日益普及以及对预防保健的重视也增加了诊所和医院对疫苗的需求。

占比最大的地区：

由于在旨在降低儿童死亡率的政府免疫计划的支持下，人们对肺炎链球菌感染的认识不断提高，预计亚太地区将在预测期内占据最大的市场占有率。都市化进程的加速和卫生基础设施的改善也促进了疫苗向不同人群的获取和分发。此外，不断增长的老年人口（特别容易受到肺炎链球菌感染）也增加了需求。与全球卫生组织的合作伙伴关係和津贴正在进一步提高疫苗接种率，而印度和中国公司的本地生产努力正在帮助使疫苗变得更便宜和容易获得。

复合年增长率最高的地区：

由于对免疫接种益处的高度认识、政府强有力的医疗保健计划以及保险系统全面的疫苗覆盖范围，预计北美在预测期内的复合年增长率最高。发达的医疗保健基础设施使人们能够广泛获得疫苗接种，特别是对于儿童、老年人和慢性疾病患者等弱势群体。主要製药公司的持续研究和开发也支持推出具有更广泛血清型覆盖范围的先进疫苗。此外，公共卫生工作和常规疫苗接种建议也促进了该地区疫苗的高接种率。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争标基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球肺炎链球菌疫苗市场：依产品类型

  • 普瑞那 13 (PCV13)
  • Pneumovax 23 (PPSV23)
  • 瓦克努·万斯 (PCV15)
  • 新产品和研发线产品
  • 新弗洛里克斯
  • 肺炎球菌
  • 其他产品类型

第六章全球肺炎链球菌疫苗市场：依疫苗类型

  • 肺炎链球菌结合疫苗 (PCV)
  • 肺炎链球菌多醣体疫苗（PPSV）

第七章全球肺炎链球菌疫苗市场：依年龄组别

  • 儿科的
  • 成人
  • 进阶的

第八章全球肺炎链球菌疫苗市场：依通路划分

  • 销售合作公司
  • 非政府组织（NGO）
  • 政府机关

第九章全球肺炎链球菌疫苗市场：依最终用户分类

  • 医院和诊所
  • 公共卫生机构与免疫规划
  • 门诊手术中心
  • 家庭健康环境
  • 零售药房
  • 网路药房
  • 其他最终用户

第十章全球肺炎链球菌疫苗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、合作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十二章 公司概况

  • Pfizer Inc.
  • Merck & Co., Inc.
  • Sanofi SA
  • GlaxoSmithKline plc
  • Serum Institute of India Pvt. Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca
  • Bharat Biotech
  • SK Bioscience
  • Johnson & Johnson
  • Biological E. Limited
  • Sinovac Biotech Ltd.
  • LG Chem Ltd.
  • Panacea Biotec Ltd.
  • Walvax Biotechnology Co., Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Indian Immunologicals Ltd.
  • Novartis AG
Product Code: SMRC27867

According to Stratistics MRC, the Global Pneumococcal Vaccine Market is accounted for $8.80 billion in 2024 and is expected to reach $13.08 billion by 2030 growing at a CAGR of 6.8% during the forecast period. A pneumococcal vaccination is a prophylactic injection intended to guard against infections brought on by the Streptococcus pneumoniae bacterium, which can result in grave conditions like sepsis, meningitis, and pneumonia. Pneumococcal conjugate vaccines (PCV), such as PCV13, and pneumococcal polysaccharide vaccines (PPSV), such as PPSV23, are the two primary varieties. For vulnerable groups, particularly small children, the elderly, and those with compromised immune systems, these vaccinations are essential. They function by boosting the immune system's capacity to identify and attack pneumococcal bacteria.

According to the data published by the UN International Children's Emergency Fund (UNICEF) in November 2023, around 2,000 children were globally affected by pneumonia on a daily basis.

Market Dynamics:

Driver:

Growing prevalence of pneumococcal diseases

Pneumococcal vaccination demand is largely driven by the rising incidence of pneumococcal illnesses including meningitis and pneumonia. These infections are a major worldwide health burden, especially when they affect young children and the elderly. The availability of efficient vaccinations and growing awareness of the severe health risks linked to pneumococcal infections are driving market expansion. Pneumococcal vaccination demand is expected to increase gradually as global healthcare systems place a greater emphasis on public health campaigns and preventive measures.

Restraint:

Disruptions in supply chain

The pneumococcal vaccine industry is greatly impacted by production and supply chain disruptions, which may result in vaccine shortages, postponed vaccination schedules, and jeopardized public health initiatives. Manufacturing issues like scarce raw materials or strict quality control requirements that impede output can cause these interruptions. Additionally, timely vaccination distribution is hampered by logistical problems, especially in rural and low-income areas, such as poor cold chain infrastructure, transportation delays, or geopolitical factors.

Opportunity:

Increasing awareness and immunization programs

As government initiatives and campaigns by organizations like the World Health Organization (WHO) and UNICEF try to educate the public on the hazards of pneumococcal infections, rising awareness and immunization programs are important factors driving the pneumococcal vaccine market. To encourage early immunization and stop the spread of disease, these initiatives focus on high-risk populations, such as the elderly and newborns. Widespread vaccination campaigns increase access to vaccinations, which boosts global public health outcomes and contributes to market growth overall, particularly in low- and middle-income nations.

Threat:

High cost of vaccination

Pneumococcal vaccination's high price is a major barrier to availability for low-income groups and in nations with tight healthcare budgets. Advanced manufacturing techniques are needed to produce vaccines like PPSV23 and Prevnar 13, which raises the price. Even while some public health initiatives offer free or heavily discounted vaccines, financial constraints may still prevent universal availability. This cost barrier is particularly problematic in underdeveloped nations, as many people are discouraged from getting vaccinated due to the high out-of-pocket expenses, which affects overall vaccination rates and raises the risk of disease.

Covid-19 Impact

The pneumococcal vaccination market was greatly impacted by the COVID-19 pandemic, which carried with it both opportunities and challenges. Initially, vaccination programs were hampered by disruptions in healthcare services and supply chains, which resulted in delays in immunization schedules. Pneumococcal vaccinations, however, are in high demand as a result of the pandemic's increased awareness of respiratory illnesses and larger public health campaigns. The necessity of preventing pneumonia, especially in susceptible groups, prompted governments to step up immunization initiatives. As a result, the market is anticipated to expand as healthcare systems adjust and give pneumococcal vaccination equal weight with COVID-19 initiatives.

The pediatric segment is expected to be the largest during the forecast period

The pediatric segment is estimated to be the largest. Significant health risks are presented by the high prevalence of pneumococcal illnesses in newborns and young children, including meningitis and pneumonia. Demand is being increased by government initiatives and public health programs that highlight the significance of childhood vaccines. Further propelling market expansions in the pediatric sector are the availability of efficacious pneumococcal vaccines and parents' growing knowledge of the advantages of immunization.

The hospitals and clinics segment is expected to have the highest CAGR during the forecast period

The hospitals and clinics segment is anticipated to witness the highest CAGR during the forecast period. These healthcare centers are essential for delivering vaccinations, especially to susceptible groups including young children, the elderly, and people with weakened immune systems. Healthcare professionals are encouraged to offer pneumococcal vaccines by government programs that promote immunization and reimbursement policies for vaccine administration. Additionally, the growing prevalence of pneumococcal infections and the emphasis on preventative healthcare are fuelling the need for vaccines in clinics and hospitals.

Region with largest share:

Asia Pacific is expected to have the largest market share during the forecast period due to rising awareness of pneumococcal diseases, supported by government-backed immunization programs aimed at reducing child mortality rates. Increasing urbanization and improved healthcare infrastructure also facilitate vaccine access and distribution across diverse populations. Additionally, a growing geriatric population, particularly vulnerable to pneumococcal infections, amplifies demand. Partnerships with global health organizations and subsidies further boost vaccination rates, while local production efforts by companies in India and China help make vaccines more affordable and accessible.

Region with highest CAGR:

North America is projected to witness the highest CAGR over the forecast period, owing to high awareness of immunization benefits, robust government healthcare programs, and comprehensive vaccine coverage under insurance plans. The established healthcare infrastructure enables wide access to vaccination, particularly for vulnerable groups like children, the elderly, and those with chronic illnesses. Ongoing research and development by key pharmaceutical players also support the introduction of advanced vaccines with broader serotype coverage. Additionally, public health initiatives and routine vaccination recommendations contribute to high vaccine adoption rates across the region.

Key players in the market

Some of the key players profiled in the Pneumococcal Vaccine Market include Pfizer Inc., Merck & Co., Inc., Sanofi S.A., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Astellas Pharma Inc., AstraZeneca, Bharat Biotech, SK Bioscience, Johnson & Johnson, Biological E. Limited, Sinovac Biotech Ltd., LG Chem Ltd., Panacea Biotec Ltd., Walvax Biotechnology Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Indian Immunologicals Ltd., and Novartis AG.

Key Developments:

In April 2024, Merck presented the results of the phase 3 clinical trial STRIDE-10 for an investigational 21-valent pneumococcal conjugate vaccine developed for adults.

In January 2024, Pfizer Inc. received marketing authorization from the Committee of Medicinal Products designed for Human Use (CHMP) of the European Medicines Agency (EMA) for its 20-valent pneumococcal conjugate vaccine candidate (20vPnC).

In April 2023, Pfizer Inc. received FDA approval for Prevnar 20 to prevent Invasive Pneumococcal Disease (IPD) in infants.

Product Types Covered:

  • Prevnar 13 (PCV13)
  • Pneumovax 23 (PPSV23)
  • Vaxneuvance (PCV15)
  • New and Pipeline Products
  • Synflorix
  • Pneumosil
  • Other Product Types

Vaccine Types Covered:

  • Pneumococcal Conjugate Vaccine (PCV)
  • Pneumococcal Polysaccharide Vaccine (PPSV)

Age Groups Covered:

  • Pediatric
  • Adult
  • Geriatric

Distribution Channels Covered:

  • Distribution Partner Companies
  • Non-Governmental Organizations (NGOs)
  • Government Authorities

End Users Covered:

  • Hospitals and Clinics
  • Public Health Agencies and Immunization Programs
  • Ambulatory Surgical Centers
  • Home Healthcare Settings
  • Retail Pharmacies
  • Online Pharmacies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pneumococcal Vaccine Market, By Product Type

  • 5.1 Introduction
  • 5.2 Prevnar 13 (PCV13)
  • 5.3 Pneumovax 23 (PPSV23)
  • 5.4 Vaxneuvance (PCV15)
  • 5.5 New and Pipeline Products
  • 5.6 Synflorix
  • 5.7 Pneumosil
  • 5.8 Other Product Types

6 Global Pneumococcal Vaccine Market, By Vaccine Type

  • 6.1 Introduction
  • 6.2 Pneumococcal Conjugate Vaccine (PCV)
  • 6.3 Pneumococcal Polysaccharide Vaccine (PPSV)

7 Global Pneumococcal Vaccine Market, By Age Group

  • 7.1 Introduction
  • 7.2 Pediatric
  • 7.3 Adult
  • 7.4 Geriatric

8 Global Pneumococcal Vaccine Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Distribution Partner Companies
  • 8.3 Non-Governmental Organizations (NGOs)
  • 8.4 Government Authorities

9 Global Pneumococcal Vaccine Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals and Clinics
  • 9.3 Public Health Agencies and Immunization Programs
  • 9.4 Ambulatory Surgical Centers
  • 9.5 Home Healthcare Settings
  • 9.6 Retail Pharmacies
  • 9.7 Online Pharmacies
  • 9.8 Other End Users

10 Global Pneumococcal Vaccine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Pfizer Inc.
  • 12.2 Merck & Co., Inc.
  • 12.3 Sanofi S.A.
  • 12.4 GlaxoSmithKline plc
  • 12.5 Serum Institute of India Pvt. Ltd.
  • 12.6 Astellas Pharma Inc.
  • 12.7 AstraZeneca
  • 12.8 Bharat Biotech
  • 12.9 SK Bioscience
  • 12.10 Johnson & Johnson
  • 12.11 Biological E. Limited
  • 12.12 Sinovac Biotech Ltd.
  • 12.13 LG Chem Ltd.
  • 12.14 Panacea Biotec Ltd.
  • 12.15 Walvax Biotechnology Co., Ltd.
  • 12.16 Mitsubishi Tanabe Pharma Corporation
  • 12.17 Indian Immunologicals Ltd.
  • 12.18 Novartis AG

List of Tables

  • Table 1 Global Pneumococcal Vaccine Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Pneumococcal Vaccine Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global Pneumococcal Vaccine Market Outlook, By Prevnar 13 (PCV13) (2022-2030) ($MN)
  • Table 4 Global Pneumococcal Vaccine Market Outlook, By Pneumovax 23 (PPSV23) (2022-2030) ($MN)
  • Table 5 Global Pneumococcal Vaccine Market Outlook, By Vaxneuvance (PCV15) (2022-2030) ($MN)
  • Table 6 Global Pneumococcal Vaccine Market Outlook, By New and Pipeline Products (2022-2030) ($MN)
  • Table 7 Global Pneumococcal Vaccine Market Outlook, By Synflorix (2022-2030) ($MN)
  • Table 8 Global Pneumococcal Vaccine Market Outlook, By Pneumosil (2022-2030) ($MN)
  • Table 9 Global Pneumococcal Vaccine Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 10 Global Pneumococcal Vaccine Market Outlook, By Vaccine Type (2022-2030) ($MN)
  • Table 11 Global Pneumococcal Vaccine Market Outlook, By Pneumococcal Conjugate Vaccine (PCV) (2022-2030) ($MN)
  • Table 12 Global Pneumococcal Vaccine Market Outlook, By Pneumococcal Polysaccharide Vaccine (PPSV) (2022-2030) ($MN)
  • Table 13 Global Pneumococcal Vaccine Market Outlook, By Age Group (2022-2030) ($MN)
  • Table 14 Global Pneumococcal Vaccine Market Outlook, By Pediatric (2022-2030) ($MN)
  • Table 15 Global Pneumococcal Vaccine Market Outlook, By Adult (2022-2030) ($MN)
  • Table 16 Global Pneumococcal Vaccine Market Outlook, By Geriatric (2022-2030) ($MN)
  • Table 17 Global Pneumococcal Vaccine Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 18 Global Pneumococcal Vaccine Market Outlook, By Distribution Partner Companies (2022-2030) ($MN)
  • Table 19 Global Pneumococcal Vaccine Market Outlook, By Non-Governmental Organizations (NGOs) (2022-2030) ($MN)
  • Table 20 Global Pneumococcal Vaccine Market Outlook, By Government Authorities (2022-2030) ($MN)
  • Table 21 Global Pneumococcal Vaccine Market Outlook, By End User (2022-2030) ($MN)
  • Table 22 Global Pneumococcal Vaccine Market Outlook, By Hospitals and Clinics (2022-2030) ($MN)
  • Table 23 Global Pneumococcal Vaccine Market Outlook, By Public Health Agencies and Immunization Programs (2022-2030) ($MN)
  • Table 24 Global Pneumococcal Vaccine Market Outlook, By Ambulatory Surgical Centers (2022-2030) ($MN)
  • Table 25 Global Pneumococcal Vaccine Market Outlook, By Home Healthcare Settings (2022-2030) ($MN)
  • Table 26 Global Pneumococcal Vaccine Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 27 Global Pneumococcal Vaccine Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 28 Global Pneumococcal Vaccine Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.